INCYTE CORP (INCY)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for INCY
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| INCY | Chair of the Board | 59 | ["Managing Member of Baker Bros. Advisors LP","experienced investor in life sciences companies","significant strategic and financial expertise","extensive knowledge of the life sciences and biopharmaceuticals industries"] | ["Nominating and Corporate Governance","Compensation","Nominating and Corporate Governance Committee"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| MDGL | Independent Chairman of the Board of Directors and Class I Director | 59 | ["Managing Member of Baker Bros. Advisors LP","Experience investing in life sciences companies","Experience serving on board of directors of other public companies in the life sciences industry"] | ["Audit","Compensation"] | 2026 |
| ACAD | Director | 59 | [] | [] | 2026 |
| DNLI | Director | 58 | [] | [] | 2025 |
Biography sourced from the proxy statement filing.
Mr. Baker is a Managing Member of Baker Bros. Advisors LP ( BBA ), a biotechnology-focused investment adviser to fund partnerships whose investors are primarily endowments and foundations. Mr. Baker founded BBA, together with his brother Felix Baker, in 2000. Prior to BBA, Mr. Baker was a portfolio manager at Tisch Financial Management from 1994 to 1999. Previously, Mr. Baker was employed from 1988 to 1993 by the private equity investment arm of Credit Suisse First Boston Corporation. The Board has concluded that Julian C. Baker should serve on the Board because he is an experienced investor in many life sciences companies. He brings to the Board significant strategic and financial expertise and extensive knowledge of the life sciences and biopharmaceuticals industries as a result of his investments in and service as a director of other publicly and privately held life sciences companies.